Last Updated : June 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Saxenda | liraglutide | Chronic weight management in adults | Do not reimburse | Complete | ||
Scemblix | asciminib | Philadelphia chromosome-positive chronic myeloid leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Sebivo | Telbivudine | Hepatitis B (chronic) | Do not list | Complete | ||
Seebri | Glycopyrronium bromide | Chronic obstructive pulmonary disease | List with criteria/condition | Complete | ||
Segluromet | ertugliflozin and metformin hydrochloride | Diabetes mellitus, Type 2 | Do not reimburse | Complete | ||
Semglee | insulin glargine | Diabetes mellitus, Type 1 & 2 | Withdrawn | |||
Sensipar | Cinacalcet hydrochloride | Secondary hyper-parathyroidism in chronic kidney disease | Do not list | Complete | ||
Signifor | Pasireotide diaspartate | Cushing’s disease | Do not list | Complete | ||
Siliq | brodalumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
Silkis | Calcitriol | Psoriasis, mild to moderate plaque | Do not list | Complete | ||
Simbrinza | Brinzolamide / brimonidine | Glaucoma and ocular hypertension | List | Complete | ||
Simponi | Golimumab | Ulcerative colitis | Do not list at the submitted price | Complete | ||
Simponi | Golimumab | Arthritis, Rheumatoid | List in a similar manner | Complete | ||
Simponi | Golimumab | Arthritis, psoriatic | List in a similar manner | Complete | ||
Simponi | Golimumab | Ankylosing spondylitis | List in a similar manner | Complete | ||
Simponi I.V. | Golimumab | Arthritis, rheumatoid | List with criteria/condition | Complete | ||
Sivextro | Tedizolid phosphate | Acute bacterial skin and skin structure infections | Withdrawn | |||
Skyrizi | risankizumab | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
Skyrizi | risankizumab | Crohn's disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Slynd | drospirenone | Contraceptive, oral | Reimburse with clinical criteria and/or conditions | Active | ||
Sogroya | somapacitan | Growth Hormone Deficiency (GHD) | Reimburse with clinical criteria and/or conditions | Complete | ||
Sohonos | palovarotene | Fibrodysplasia Ossificans Progressiva | Reimburse with clinical criteria and/or conditions | Complete | ||
Soliqua | lixisenatide + insulin glargine | Diabetes mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
Soliris | eculizumab | Neuromyelitis optica spectrum disorder | Reimburse with clinical criteria and/or conditions | Complete | ||
Soliris | Eculizumab | Hemolytic Uremic Syndrome, Atypical | Do not list | Complete |